Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: Studies in animal models

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 1, 2015, Pages 1-13

  Calvo Ochoa, Erika ^a   Arias, Clorinda ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Alzheimer's disease; Cognitive decline; Diabetes; Hippocampal dysfunction; Insulin resistance; Obesity

Indexed keywords

INSULIN; INSULIN RECEPTOR;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; HIPPOCAMPUS; HUMAN; INSULIN RESISTANCE; LIPID DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUGAR INTAKE; SYNAPSE; ANIMAL; COGNITION; COGNITION DISORDERS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; COGNITION; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; INSULIN; OBESITY; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84920945408     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2531     Document Type: Review

References (164)

1. Kraegen EW, Clark PW, Jenkins AB, et al. Development of muscle insulin resistance after liver insulin resistance in high-fat fed rats. Diabetes 1991; 40: 1397-1403.
2. The state of food and agriculture. Food and agriculture organization of the United Nations, 2013. ISBN 978-92-5-107671-2.
3. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378(9785): 31-40.
4. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007; 87: 507-520.
5. Lind L, Lithell H. Hypertension, hyperlipidemia, insulin resistance and obesity: parts of a metabolic syndrome. Blood Pres Sup. 1992; 4: 49-54.
6. Meigs JB. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 2000; 152: 908-911.
7. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing 2010; 39: 8-10.
8. Schrijvers EMC, Witteman JCM, Sijbrands EJG, Hofman A, Koudstaal PJ, Breteler MMB. Insulin metabolism and the risk of Alzheimer disease The Rotterdam Study. Neurology 2010; 75: 1982-1987.
9. Sima AAF. Encephalopathies: the emerging diabetic complications. Acta Diabetol. 2010; 47: 279-293.
10. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease The Hisayama study. Neurology 2010; 75: 764-770.
11. Viscogliosi G, Andreozzi P, Chiriac IM, et al. Screening cognition in the elderly with metabolic syndrome. Metab. Syndr. Relat. Disord. 2012; 10: 358-362.
12. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 2007; 4: 147-152.
13. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010; 31: 224-243.
14. Ciobica A, Padurariu M, Bild W, Stefanescu C. Cardiovascular risk factors as potential markers for mild cognitive impairment and Alzheimer's disease. Psychiatr. Danub. 2011; 23(4): 340-6.
15. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. In Vecsei L, ed. Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection: A Symposium in Abel Lajtha's Honour 2004; 135-152
16. Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurob. 2013; 47: 145-171.
17. Adamo ML, Shemer J, Roberts CT Jr, LeRoith D. Insulin and insulin-like growth factor-I induced phosphorylation in neurally derived cells. Ann. N. Y. Acad. Sci. 1993 Aug 27; 692: 113-25.
18. Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosc. 1999; 19: 7300-7308.
19. Werther GA, Hogg A, Oldfield BJ, et al. Localization and characterization of insulin-receptors in rat-brain and pituitary-gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987; 121: 1562-1570.
20. Havrankova J, Roth J. Insulin receptors are widely distributed in central nervous-system of rat. Nature 1978; 272: 827-829.
21. Zhao WQ, Chen H, Xu H, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 1999; 274: 34893-34902.
22. Margolis R, Altzuler A. Insulin in the cerebrospinal fluid. Nature 1967; 215: 1375-1376.
23. Baura GD, Foster DM, Porte D, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in-vivo: a mechanism for regulated insulin delivery to the brain. J. Clin. Invest. 1993; 92: 1824-1830.
24. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Curr. Pharm. Des. 2003; 9: 795-800.
25. Valenciano AI, Corrochano S, de Pablo F, de la Villa P, de la Rosa EJ. Proinsulin/insulin is synthesized locally and prevents caspase- and cathepsin-mediated cell death in the embryonic mouse retina. J. Neurochem. 2006; 99: 524-36.
26. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Therap. 2012; 136: 82-93.
27. Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS. Insulin gene-expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 1994; 269: 8445-8454.
28. Devaskar SU, Singh BS, Carnaghi LR, Rajakumar PA, Giddings SJ. Insulin II gene expression in rat central nervous system. Regul. Pept. 1993; 48: 55-63.
29. Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res. 1996; 736: 16-27.
30. Lacroix MC, Badonnel K, Meunier N, et al. Expression of insulin system in the olfactory epithelium: first approaches to its role and regulation. J. Neuroendocrinol. 2008; 20(10): 1176-90.
31. Kuwabara T, Kagalwala MN, Onuma Y, et al. Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 2011; 3(12): 742-54.
32. Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism - an (18)fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51: 3384-3390.
33. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 2004; 490(1-3): 71-81.
34. Huang TJ, Verkhratsky A, Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol Cell Neurosc. 2005; 28: 42-54.
35. Duarte AI, Proenca T, Oliveira CR, Santos MS, Rego AC. Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 2006; 55: 2863-2870.
36. Duarte AI, Santos P, Oliveira CR, Santos MS, Rego AC. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3 beta signaling pathways and changes in protein expression. BBA-Mol Cell Res. 2008; 1783: 994-1002.
37. Skeberdis VA, Lan JY, Zheng X, Zukin RS, Bennett MVL. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 3561-3566.
38. van der Heide LP, Kamal A, Artola A, Gispen WH, Ramakers GMJ. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J. Neurochem. 2005; 94: 1158-1166.
39. Sauter A, Goldstein M, Engel J, Ueta K. Effect of insulin on central catecholamines. Brain Res. 1983; 260: 330-333.
40. Boyd FT, Clarke DW, Muther TF, Raizada MK. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J. Biol. Chem. 1985; 260: 5880-5884.
41. Wan Q, Xiong ZG, Man HY, et al. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature. 1997; 14; 388(6643): 686-90.
42. Cid MP, Arce A, Salvatierra NA. Acute stress or systemic insulin injection increases flunitrazepam sensitive-GABAA receptor density in synaptosomes of chick forebrain: modulation by systemic epinephrine. Stress 2008; 11: 101-7.
43. Chiu S-L, Cline HT. Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010; 5. DOI:10.1186/1749-8104-5-7
44. McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur. J. Pharmacol. 2004; 19;490: 13-24.
45. Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009; 1296: 35-45.
46. Heras-Sandoval D, Ferrera P, Arias C. Amyloid-beta protein modulates insulin signaling in presynaptic terminals. Neuroch Res. 2012; 37: 1879-1885.
47. Wang JL, Obici S, Morgan K, Barzilai N, Feng ZH, Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001; 50: 2786-2791.
48. Samuel VT, Liu ZX, Qu XQ, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004; 279: 32345-32353.
49. Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 2000; 68(4): 509-14.
50. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J. Neurosci. 2009; 20; 29(20): 6734-51.
51. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007; 86: 136-142.
52. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001; 74(4): 270-80.
53. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J. Clin. Endocrinol. Metab. 2012; 97(2): 366-76.
54. Krug R, Benedict C, Born J, Hallschmid M. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J. Clin. Endocrinol. Metab. 2010; 95: E468-E472.
55. Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int. J. Obes. 2008; 32: 275-278.
56. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer Dis. 2008; 13: 323-331.
57. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br. Med. J. 1997; 315: 1045-1049.
58. Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosc. 2006; 23: 3375-3384.
59. Sui L, Wang J, Li B-M. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn. Mem. 2008; 15: 762-776.
60. Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 2019-2022.
61. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimer Dis. 2005; 7: 63-80.
62. Ronnemaa E, Zethelius B, Sundelof J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71: 1065-1071.
63. Frisardi V, Imbimbo BP. Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk introduction. J Alzheimer Dis. 2010; 30: S1-S4.
64. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011; 77: 1126-1134.
65. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012; 9: 35-66.
66. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 1998; 105: 415-422.
67. Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res. Rev. 2012; 9: 399-417.
68. Burns JM, Honea RA, Vidoni ED, Hutfles LJ, Brooks WM, Swerdlow RH. Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. BBA- Mol Bas Dis. 1822; 2012: 333-339.
69. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007; 56: 211-216.
70. Pavlik V, Massman P, Barber R, Doody R, Tarcc. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimer Dis. 2013; 34: 449-456.
71. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005; 62: 1556-1560.
72. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Br. Med. J. 2005; 330: 1360-1362B.
73. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 2007; 4: 103-109.
74. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71: 1057-1064.
75. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 2003; 163: 1524-1528.
76. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia aging study. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2255-2260.
77. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998; 21: 398-402.
78. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J. Am. Geriatr. Soc. 2007; 55: 758-762.
79. Dik MG, Jonker C, Comijs HC, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007; 30: 2655-2660.
80. van den Berg E, Biessels GJ, de Craen AJM, Gussekloo J, Westendorp RGJ. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69: 979-985.
81. Roriz-Cruz M, Rosset I, Wada T, et al. Cognitive impairment and frontal-subcortical geriatric syndrome are associated with metabolic syndrome in a stroke-free population. Neurobiol. Aging 2007; 28: 1723-1736.
82. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk of Alzheimer's disease or vascular dementia incident: study within the cohort 3C. Diabetes Metab. 2009; 35: A48-A49.
83. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J. Neurol. Neurosurg. Psychiatry 2010; 81: 433-440.
84. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 1997; 145: 301-308.
85. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-847.
86. Ott A, Stolk RP, van Harskamp F, Pols HAP, Hofman A, Breteler MMB. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999; 53: 1937-1942.
87. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch. Intern. Med. 2000; 160: 174-180.
88. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-1192.
89. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 2001; 154: 635-641.
90. Grodstein F, Wilson RS, Chen J, Manson JE. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 2001; 24: 1060-1065.
91. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults - A 4-year prospective study of the Rancho Bernardo Study Cohort. Arch. Intern. Med. 2004; 164: 1327-1333.
92. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658-663.
93. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA-J Am Med Assoc. 2004; 292: 2237-2242.
94. Beeri MS, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63: 1902-1907.
95. Xu W, Caracciolo B, Wang H-X, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010; 59: 2928-2935.
96. Blagosklonny MV. Aging and immortality - quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5: 2087-2102.
97. Freude S, Plum L, Schnitker J, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005; 54: 3343-3348.
98. Maesako M, Uemura K, Kubota M, et al. Insulin regulates Presenilin 1 localization via PI3K/Akt signaling. Neurosc Lett. 2010; 483: 157-161.
99. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002; 112: 803-814.
100. Winocur G, Greenwood CE. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging 2005; 26: S46-S49.
101. Lindqvist A, Mohapel P, Bouter B, et al. High-fat diet impairs hippocampal neurogenesis in male rats. Eur. J. Neurol. 2006; 13: 1385-1388.
102. Stranahan AM, Norman ED, Lee K, et al. Diet-induced insulin resistance impairs Hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008; 18: 1085-1088.
103. Granholm A-C, Bimonte-Nelson HA, Moore AB, Nelson ME, Freeman LR, Sambamurti K. Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J Alzheimer Dis. 2008; 14: 133-145.
104. Farr SA, Yamada KA, Butterfield DA, et al. Obesity and Hypertriglyceridemia produce cognitive impairment. Endocrinology 2008; 149: 2628-2636.
105. Jurdak N, Kanarek RB. Sucrose-induced obesity impairs novel object recognition learning in young rats. Physiol. Behav.. 2009; 8;96(1): 1-5.
106. Boitard C, Etchamendy N, Sauvant J, et al. Juvenile, but not adult exposure to high-fat diet impairs relational memory and hippocampal neurogenesis in mice. Hippocampus 2012; 22: 2095-2100.
107. Valladolid-Acebes I, Merino B, Principato A, et al. High-fat diets induce changes in hippocampal glutamate metabolism and neurotransmission. Am. J. Physiol. Endocrinol. Metab. 2012; 302: E396-E402.
108. Freeman LR, Granholm AC. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. J. Cereb. Blood Flow Metab. 2012; 32(4): 643-53.
109. McNay EC, Ong CT, McCrimmon RJ, Cresswell J, Bogan JS, Sherwin RS. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem. 2010; 93: 546-553.
110. Shie FS, Jin LW, David GC, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002; 13: 455-459.
111. Puig KL, Floden AM, Adhikari R, Golovko MY, Combs CK. Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS One 2012; 7.
112. Levin-Allerhand JA, Smith JD. Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality. J. Mol. Neurosci. 2002; 19: 163-166.
113. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2007; 282: 36275-36282.
114. Studzinski CM, Li F, Bruce-Keller AJ, et al. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. J. Neurochem. 2009; 108: 860-866.
115. Julien C, Tremblay C, Phivilay A, et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging 2010; 31: 1516-1531.
116. Van Dyke K, Jabbour N, Hoeldtke R, Van Dyke C, Van Dyke M. Oxidative/nitrosative stresses trigger type I diabetes: preventable in streptozotocin rats and detectable in human disease. In: Laskin DL, ed. Oxidative/Nitrosative Stress Dis, 2010:138-145.
117. Biessels GJ, Kamal A, Urban IJA, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 1998; 800: 125-135.
118. Magariños AM, McEwen BS. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc. Natl. Acad. Sci. U. S. A.. 2000; 26;97(20): 11056-61.
119. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosc. 2008; 11: 309-317.
120. Shingo AS, Kanabayashi T, Murase T, Kito S. Cognitive decline in STZ-3V rats is largely due to dysfunctional insulin signalling through the dentate gyrus. Behav. Brain Res. 2012; 229: 378-383.
121. Clodfelder-Miller BJ, Zmijewska AA, Johnson GVW, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006; 55: 3320-3325.
122. Planel E, Tatebayashi Y, Miyasaka T, et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosc. 2007; 27: 13635-13648.
123. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009; 150(12): 5294-301.
124. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009; 19;4(11): e7917
125. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 2012; 7(3): e32792.
126. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 1998; 112: 1199-1208.
127. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, De la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimer Dis. 2006; 9: 13-33.
128. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 2006; 96: 1005-1015.
129. Prickaerts J, Fahrig T, Blokland A. Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Behav. Brain Res. 1999; 102: 73-88.
130. Deng Y, Li B, Lu Y, Iqbal K, Grundke-Iqbal I, Gong C-X. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of Tau and neurofilaments in the brain implication for Alzheimer's disease. Am. J. Pathol. 2009; 175: 2089-2098.
131. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 2007; 101(3): 757-70.
132. Shonesy BC, Thiruchelvam K, Parameshwaran K, et al. Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol. Aging 2012; 33(2): 430.e5-18.
133. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer Dis. 2006; 10: 89-109.
134. Agrawal R, Tyagi E, Shukla R, Nath C. A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology 2009; 56(4): 779-87.
135. Henneberg N, Hoyer S. Desensitization of the neuronal insulin-receptor - a new approach in the ethiopathogenesis of late-onset sporadic dementia of the Alzheimer-type (SDAT). Arch. Gerontol. Geriatr. 1995; 21: 63-74.
136. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann. N. Y. Acad. Sci. 1999; 893: 290-3.
137. Arias C, Montiel T, Quiroz-Baez R, Massieu L. Beta-amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Exp. Neurol. 2002; 176: 163-174.
138. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer Dis. 2005; 8: 247-268.
139. Montiel T, Quiroz-Baez R, Massieu L, Arias C. Role of oxidative stress on beta-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: protection by antioxidants. Exp. Neurol. 2006; 200: 496-508.
140. Zucker LM, Antoniades H. Insulin and obesity in Zucker genetically obese rat fatty. Endocrinology 1972; 90: 1320.
141. Chan TM, Young KM, Hutson NJ, Brumley FT, Exton JH. Hepatic metabolism of genetically diabetic (db/db) mice. 1. Carbohydrate metabolism. Am. J. Physiol. 1975; 229: 1702-1712.
142. Kodama H, Fujita M, Yamaguchi I. Development of hyperglycemia and insulin resistance in conscious genetically diabetic (C57BL/KSJ db/db) mice. Diabetologia 1994; 37: 739-744.
143. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 2007; 125: 451-472.
144. Zhang YY, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homolog. Nature 1994; 372: 425-432.
145. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
146. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002; 113: 607-615.
147. Gerges NZ, Aleisa AM, Alkadhi KA. Impaired long-term potentiation in obese Zucker rats: possible involvement of presynaptic mechanism. Neuroscience 2003; 120: 535-539.
148. Alzoubi KH, Aleisa AM, Alkadhi KA. Impairment of long-term potentiation in the CA1, but not dentate gyrus, of the hippocampus in obese Zucker rats. J. Mol. Neurosci. 2005; 27: 337-346.
149. Winocur G, Greenwood CE, Piroli GG, et al. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav. Neurosci. 2005; 119: 1389-1395.
150. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimer Dis. 2009; 16: 741-761.
151. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and a beta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 7036-7041.
152. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
153. Schubert M, Gautam D, Surjo D, Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A.. 2004; 2;101(9): 3100-5.
154. Qiu WQ, Walsh DM, Ye Z. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998; 4;273(49): 32730-8.
155. Xie L, Helmerhorst E, Taddei K, Plewright B, van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosc. 2002; 22(10): RC221.
156. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 2000; 14: 1015-1022.
157. Gasparini L, Gouras GK, Wang R, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosc. 2001; 21: 2561-2570.
158. Costantini C, Scrable H, Puglielli L. An aging pathway controls the TrkA to p75(NTR) receptor switch and amyloid beta-peptide generation. EMBO J. 2006; 25: 1997-2006.
159. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 2005; 33: 1041-1044.
160. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong C-X. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011; 225: 54-62.
161. Talbot K, Wang H-Y, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012; 122: 1316-1338.
162. Cuervo AM. Autophagy: many paths to the same end. Mol Cel Biochem. 2004; 263: 55-72.
163. McClean PL, Gault VA, Harriott P, Hoelscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 2010; 630: 158-162.
164. Bomfim TR, Forny-Germano L, Sathler LB. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest.; 2012; 2;122(4): 1339-53.